...A. We launched our fourth therapy in the first gene therapy for boys with Duchenne muscular dystrophy. B. We continue to drive great performance with our 3 PMOs and importantly, on a non-GAAP basis, we achieved profitability placing us in ever more rarified biotech territory. C. As you will have seen in our release, led by an exceptional launch of ELEVIDYS and continuing performance of our 3 approved PMOs, EXONDYS, VYONDYS and AMONDYS. D. Third quarter total revenue came in at $332 million, and total net product revenue stands at $309.32 million growing 49% over the same quarter last year, reflecting the team's ability to execute and serve Duchenne patients, ELEVIDYS net product revenue came in at $69.11 million, nearly triple, mean external consensus. E. Likewise, our PMOs achieved $240.21 million in net product revenue growing 16% over the same quarter prior year, and non-GAAP earnings stood at $38 million in the quarter, a major milestone for Sarepta as we transition to a profitable...
